Specialty Pharmacy Opens The Door – For Continued PBM Antitrust Litigation
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharmacists’ suit against Express Scripts/Medco merger is mostly, but not entirely shot down; court rules that pharmacists can pursue specialty pharmacy antitrust claims against the combined pharmacy benefit managers but tosses three other claims.
You may also be interested in...
Express Scripts-Medco Merger Closes With No Divestitures Needed
The FTC voted in a split 3-1 vote to close its investigation and allow Express Scripts’ $29.1 billion acquisition of rival PBM Medco to proceed.
Express Scripts/Medco Merger's Impact On Small Pharmacies Is Focus Of Hearing
Express Scripts CEO tells House Judiciary subcommittee that the companies would not be in favor of divesting their mail order and specialty pharmaceutical businesses.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.